WALTHAM, Mass.–(BUSINESS WIRE)– Cerulean
Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing
nanoparticle-drug conjugates (NDCs), today announced that Christopher D.
T. Guiffre, President & Chief Executive Officer, will present at the JMP
Securities Life Sciences Conference in New York City on Tuesday, June 21
at 1:30 p.m. ET.
A live audio webcast of the presentation will be available on the
“Investors” section of the Company’s website, www.ceruleanrx.com
with the replay available for two weeks following the presentation.
About Cerulean Pharma
The Cerulean team is committed to improving treatment for people living
with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a
portfolio of NDCs designed to selectively attack tumor cells, reduce
toxicity by sparing the body’s normal cells, and enable therapeutic
combinations. Our first platform-generated NDC clinical candidate,
CRLX101, is in multiple clinical trials in combination with other cancer
treatments, all of which aim to unlock the power of combination therapy.
Our second platform-generated NDC clinical candidate, CRLX301, is in a
Phase 1/2a clinical trial. For more information, please visit www.ceruleanrx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160614005412/en/
Contacts
Cerulean Pharma
Nicole P. Jones, 781-209-6385
Director,
Investor Relations and Corporate Communications
njones@ceruleanrx.com
Source: Cerulean Pharma Inc.
Cet article Cerulean to Present at JMP Securities Life Sciences Conference est apparu en premier sur EEI-BIOTECHFINANCES.